apceth, the global innovator and leader in engineered mesenchymal stem cell (MSC) technology and MSC-based gene therapies, has entered a license option agreement with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd (ASX: CYP) for the use of Cynata’s proprietary Cymerus™ technology.
apceth intends to combine its proprietary platform technology for genetic modification of MSC for therapeutic application with Cynata’s unique platform Cymerus™. Cymerus™ is based on MSC derived from induced pluripotent stem cells (iPS). It will be used to create a scalable platform for genetically engineered MSC that will support the manufacturing of apceth’s off-the-shelf products at commercial scale.
Please note: today apceth Biopharma focuses solely on the CDMO business